Drug screening for skin squamous cell cancer lesions
Part of Cancer clinical trials.
This trial tests a device placed on skin cancer lesions to see which drugs might work best. It is for people with visible squamous cell carcinoma on the skin, including lesions that have come back after radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of skin cancer called squamous cell carcinoma that is visible on the skin.
- At least one skin lesion must be at least 1 cm wide and in a spot where a small device can be placed.
- You must be 18 years or older.
- You must be well enough to have a minor procedure (ECOG score 0-2).
- Your blood counts (neutrophils and platelets) must be above certain levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a special light-based technique (Raman spectroscopy) to see if it can help doctors better identify skin cancers. It is for people with either basal cell or squamous cell carcinoma who are scheduled to receive brachytherapy treatment.
This trial tests a special radiation device (DaRT) placed directly into skin cancer tumors. It is designed for patients with weakened immune systems (immunocompromised) who have a single skin cancer lesion on the skin (not spread elsewhere).
This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.
This trial tests whether taking vitamin D before a special light therapy (photodynamic therapy) can help your body fight nonmelanoma skin cancers like basal or squamous cell cancer. You may join if you are scheduled for surgery to remove a skin tumor.
This trial tests a tiny device placed directly into skin lymphoma spots to help identify which “candidate” drugs could work. It’s mainly aimed at people with measurable skin involvement from T-cell lymphoma, after they stop certain treatments for a set time.
This trial studies a blood test (ctDNA) in people with a type of skin cancer called cutaneous squamous cell carcinoma. It aims to see if the test can help track the cancer and guide treatment decisions.
Hear when a new Squamous Cell Carcinoma of the Skin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.